NCT00277875已完成2 期
The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 2
- 主要终点
- Arterial stiffening
研究概览
简要总结
Determine whether increasing arterial distensibility by decreasing advanced glycation end-product (AGE) cross-link components of vascular stiffness improves (a) endothelial-mediated vasoreactivity at rest, as assessed by flow-mediated vasodilation (FMD), and (b) endothelial-mediated vasoreactivity after exercise, as assessed by pulse perfusion-mediated vasodilation (PPMV).
详细描述
- Explore several independent variables as potential independent predictors of vascular stiffness and endothelial function. These parameters include patient age, body mass index, gender, renal disease, history of cardiovascular disease, serum cholesterol, and antihypertensive medication use.
- Provide insight into nitric oxide-dependent endothelial function in the setting of increased arterial stiffness by determination of substances in the nitric oxide signaling pathway (specifically, levels of serum cGMP; serum nitrate and nitrite; and serum asymmetric dimethylarginine [ADMA], an endogenous inhibitor of nitric oxide synthase).
- Provide insight into changes in AGE levels and collagen metabolism in response to alagebrium therapy [specifically, AGEs: pentosidine, carboxymethyllysine, carboxyethyllysine, furosine; Collagen markers: procollagen I carboxyterminal propeptide (PICP), procollagen type I N terminal propeptide (PINP), cross-linked carboxyterminal telopeptide of Type I collagen (ICTP), n-terminal propeptide of type III procollagen (PIIINP)].
- Provide insight into changes in markers of inflammation in response to alagebrium therapy [specifically, free and total serum matrix metalloproteinase-1(MMP-1), free tissue inhibitor of metalloproteinase 1 (TIMP1), intercellular adhesion molecule-1 (ICAM), P-selectin, von Willebrand factor (vWf), interleukin-6 (IL-6), and high-sensitivity C reactive protein (hs CRP)].
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- Single
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female 50 years of age or greater.
- •Diagnosed with systolic hypertension (systolic blood pressure >140 mm Hg and (less than or equal to) 200 mm Hg, and a diastolic blood pressure (less than or equal to) 95 mm Hg) and elevated pulse pressure (systolic blood pressure [SBP] minus diastolic blood pressure [DBP] greater than 60 mm Hg).
- •Normal left ventricular function (ejection fraction >55%) at baseline (Visit 3).
- •Able to perform bicycle exercise.
- •Able to read, understand and sign the informed consent after the nature of the study has been explained.
- •If sexually active, the patient agrees to use reliable contraception while participating in this study. If a woman, is surgically sterilized or post-menopausal, or has a negative serum pregnancy test.
排除标准
- •Aortic stenosis, prior known coronary artery disease (including myocardial infarction), cerebrovascular accident, or peripheral vascular disease.
- •Uncontrolled hypertension (SBP > 200/ DBP > 95 mm Hg).
- •Atrial fibrillation, diabetes mellitus treated with insulin, or chronic lung disease.
- •Any additional condition(s) which, in the opinion of the investigator, would prohibit the patient from completing the study, or not be in the best interest of the patient.
- •Treatment with nitrates, or a change in antihypertensive medications within the last 1 month.
- •Treatment with any investigational drug within 1 month prior to study drug administration.
- •Previous exposure to alagebrium.
- •AST (SGOT) or ALT (SGPT) > 2x normal limit.
- •Serum creatinine > 2.0 ng/mL.
- •Cigar/cigarette smoking.
- •Necessity to use smokeless tobacco or nicotine-containing products, or to consume caffeine, alcohol, or antioxidants starting at midnight prior to study clinic visits. NOTE: Water is allowed ad libitim.
- •Positive drug screen.
结局指标
主要结局
Arterial stiffening
Markers of endothelial function, vascular inflammation and collagen synthesis.
Local distensibility
Augmentation index (AI)
Endothelial function
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Vascular Markers During OGTT in Diabetics and First-degree RelativesDiabetes MellitusNCT02244736University of Athens100
已完成
不适用
Changes in Arterial Stiffness and Endothelial Glycocalyx in Patients With Poorly Controlled Diabetes Mellitus Type 1 or Type 2 After Optimization of Antidiabetic Medication.Diabetes MellitusNCT03010956University of Athens100
已完成
不适用
Association between endothelial glycocalyx volume and cardiovascular risk scorescardiovascular diseaseAtherosclerosisNL-OMON37440Academisch Medisch Centrum180
已完成
4 期
The Effect of Balanced Crystalloid Versus 5% Albumin on Endothelial Glycocalyx Degradation in Patients Undergoing Off-pump Coronary Artery Bypass SurgeryCoronary Artery Occlusive Disease(CAOD)NCT03699462Yonsei University106
已完成
不适用
Disturbed Blood Flow Induces Endothelial Dysfunction in Severe Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary DiseaseNCT03004352University of Split, School of Medicine27